Dr. Zhang and other partners launched Beta Chemicals, Inc. at Science Park at Yale in New Haven, CT, as a contract research organization (CRO) offering specialty chemicals and custom synthesis. Beta Chemicals evolved into Beta Pharma and in 1998 initiated its first drug discovery project. The first major breakthrough came in 2002 with the synthesis of a novel EGFR tyrosine kinase inhibitor, Icotinib. Zhang partnered with investors and in 2011 Icotinib HCl was granted marketing approval in China under the brand name Conmana®. Zhang then refocused Beta Pharma’s efforts towards Icotinib’s development globally and the company successfully filed an IND in the U.S. for Icotinib HCl and has been given approval to begin Phase I clinical trials.

Memberships/Associations/Affiliations: American Chemical Society (ACS), American Association for Cancer Research (AACR), American Society of Clinical Oncologists (ASCO), European Society of Medical Oncology (ESMO)

Dr. Jirong Peng joined Beta Pharma in 2007 and manages the overall company executive operations, routine operations of new drug development, IND/NDA registration, new drug clinical development in Asia, and strategic cooperation with business partners and local regulatory bodies. Prior to this, Peng served Beta Pharma as Vice President and Director of Chemistry. Peng brings over 30 years of experience with research and chemistry and previously oversaw scientific functions, including basic and applied research projects, as well as the development of new processes, technologies and products.

Dr. Peng obtained a Ph.D. in Organic Chemistry from Michigan State and a B.Sc. Analytical Chemistry, Lanzhou University, P. R. of China. His dissertation was titled Mechanistic Studies and Inhibition of Dehydroquinate Synthase and myo-Inositol 1-phosphate Synthase.

Memberships/Associations/Affiliations: American Chemical Society (ACS), American Association for Cancer Research (AACR), American Society of Clinical Oncologists (ASCO), European Society of Medical Oncology (ESMO)